Borato-1, 2-diaminocyclohexane platinum (II), a novel anti-tumor drug

Adnan Dibas, Jeremy Howard, Shehab Anwar, David Stewart, Amanullah Khan

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Borato-1, 2-diaminocyclohexane platinum (II) (BDP) was synthesized and compared to cisplatin (cisPt) as a potential anti-tumor drug. BDP and cisPt (0.2-20 μM) dose-dependently inhibited DNA synthesis in L1210 murine leukemia cells, DU-145 prostate cancer cells, A549 lung carcinoma cells, and MCF-7 breast cancer cells, as judged by measuring [3H]-thymidine incorporation. BDP and cisPt induced killing of L1210 murine cells by 97 and 78%, respectively. The LD50 was 35 and 14 mg/kg for BDP and cisPt, respectively. Interestingly, while cisPt (at optimal dose) induced a 100% increase in life span (ILS) of BDF1 mice bearing L1210 tumor cells, BDP (at optimal dose) induced a 200% increase in ILS in the same tumor model. In conclusion, BDP is a novel platinum derivative compound that appears more effective in increasing the ILS than cisplatin against the leukemia tumor mouse model.

Original languageEnglish
Pages (from-to)383-386
Number of pages4
JournalBiochemical and Biophysical Research Communications
Issue number2
StatePublished - 13 Apr 2000


  • Cisplatin
  • DNA synthesis
  • L1210
  • Leukemia
  • Platinum


Dive into the research topics of 'Borato-1, 2-diaminocyclohexane platinum (II), a novel anti-tumor drug'. Together they form a unique fingerprint.

Cite this